BusinessNews brief
Sling Therapeutics raises $123 million to advance thyroid eye disease drug
Drug developer Sling Therapeutics said on Wednesday it had raised $123 million to advance a late-stage trial of its experimental oral drug to treat thyroid eye disease.
Sources and context
ReutersSource headline and summary supplied via NewsData.io. First collected by NewsJaws on 2026-09-17. This is an automated news brief, not original NewsJaws reporting. Dates reflect the source publication. Feed delays may apply.